Bluejacket 6,
thank you very much for your responses. Forgive me, but I don't have a paid subscription, so I'm not able to private message. In the future, feel free to email me at latemaven@gmail.com.
For the record, I have followed Titan since 2011, and I have been invested at various times. I am not currently invested here, but I intend to buy in very soon. I'm kind of hoping that, over the next few weeks/months, it will make it's way down to anywhere in the .60s, although I know that this could be a dream never realized. If it's not there or nearly there at a certain time, I'll go ahead and buy in. I actually think that any pps under $1 is golden, but I'd like to get as much mileage as possible here. It will have to be a long and patient investment, to be sure, but I don't currently know of any "risky" stocks that are as sure of a bet as Titan is. I'm willing to invest and wait, because the potential here is so great.
Also, I want to support the work that Titan is doing, because I work in an ER and other medical facilities, and given various job-related experiences, I believe that the need for an implantable, constant-release form of Buprenophine is needed more now than ever. Widespread addiction to opiate-derived medications notwithstanding, cheap Heroin is flooding the U.S. from exterior cartels who are converting considerable percentages of their sales from marijuana to heroin, as they are looking ahead and foreseeing diminishing returns from black-market marijuana sales. Thus, cases of heroin addiction are drastically increasing over much of the country, as a steady and "affordable" supply is causing heroin to overtake meth as the addiction of choice. The need here is too great, the facts are clear, and I don't believe that the FDA will deny the next application, assuming that results from this next trial are similar to the previous Phase III trial.
Concerning Braeburn, I can't help but suspect that it has at least considered buying a controlling stake in Titan. If I understand correctly, when the agreement between the two companies was amended after the FDA's rejection, Titan was given a higher royalty from gross sales than in the original agreement, as well as royalties from other "addiction treatments" that Braeburn might acquire elsewhere, while retaining the sole rights to sales of Probuphine generated outside of the U.S. (or maybe it's outside of North America). Given those concessions, and the expense that Braeburn has taken on by agreeing to provide the capital for the new trial, it would certainly be reasonable to expect Braeburn to make the move to buy a controlling interest in Titan. What do they have to lose? They would essentially be getting back at least some of what they pay to Titan once Probuphine is licensed and is generating sales. Then, too, Braeburn would gain from profits generated from Titan's revenue generated outside of the U.S., which is not in the current agreement. While I may be mistaken, I'm under the impression that Braeburn currently owns 11% of Titan. Regardless of whether or not Braeburn buys a "controlling interest", it would do well to increase it's position before a license is granted, because the increase in share price will help offset the expenses from the second Phase III trial. Furthermore, if Braeburn's current pps of Titan stock is in the upper .90s (as reported by the Seeking Alpha article that I read earlier this summer, which I found to be convincingly thorough), I would think that Braeburn would acquire more shares of Titan before the share price goes higher, assuming they can do so legally.
However, I am not a business guru, and I still have some DD to do. Any thoughts, contrary or otherwise, are always appreciated.
GLTA
